Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 ...

PharmAla will seek to finalize the license and data sharing agreement prior to the conclusion of the 2024 calendar year. The identity of the trial Principal Investigators and institution is currently ...

The National Institute of Aging awarded a $7.3 million research grant for the study of NU-9 as a treatment for ...

The vaccine appears to be safe and effective against triple-negative breast cancer -- a type that can’t be treated with ...

WEDNESDAY, Nov. 13, 2024 (HealthDay News) -- The blockbuster GLP-1 drug semaglutide ( Ozempic, Wegovy) could curb drinking ...

The funding will make the hospital's new MRI truly state-of-the-art by adding new imaging methods, allowing users to see more ...

Diabetes is the eighth leading cause of death in the US and can lead to other conditions, including kidney failure, ...

"The entertainment value will be epic," the billionaire said.

41% parents feel they can only properly connect with their children across the dinner table, according to new research by ...

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis.

Chronic fatigue and long Covid remain poorly understood, but Dr Perrin’s unusual techniques are having surprisingly positive ...

“We look forward to evaluating the impact of Magnitude on patient outcomes and its ability to meet this growing clinical need.” The company stated that its bioresorbable ... financing round to support ...